Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

Overview of attention for article published in Diabetes, Obesity & Metabolism, February 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

policy: 1 policy source
twitter: 8 X users

guideline: 2 clinical guideline sources

Readers on

mendeley: 117 Mendeley

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 32,520 followers.

@PancreasPirata @mellitus_1 @moreNaza_ret @republikadiabet @nurivl12 @JBerian @fuensantagg73 @nerdabetic @EstiUgarte @evifdc @WeAreNotWaiting @OpenAPS @danamlewis @RosaCorcoy @fabycaal @estebanjodar https://t.co/A9R87un1sc

RT @TechnoDiabetes: #ONSET1Study results: lower PPG and HbA1c levels with #FiAsp @novonordisk @NovoNordiskSA https://t.co/i2LaT5ErMh

#ONSET1Study results: lower PPG and HbA1c levels with #FiAsp @novonordisk @NovoNordiskSA https://t.co/i2LaT5ErMh

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.